Literature DB >> 9887341

The spectrum of mutations in UBE3A causing Angelman syndrome.

P Fang1, E Lev-Lehman, T F Tsai, T Matsuura, C S Benton, J S Sutcliffe, S L Christian, T Kubota, D J Halley, H Meijers-Heijboer, S Langlois, J M Graham, J Beuten, P J Willems, D H Ledbetter, A L Beaudet.   

Abstract

Angelman syndrome (AS) is characterized by mental retardation, absence of speech, seizures and motor dysfunction. AS is caused by maternal deletions for chromosome 15q11-q13, paternal uniparental disomy (UPD), imprinting defects or loss-of-function mutations in the UBE3A locus which encodes E6-AP ubiquitin-protein ligase. The UBE3A gene is imprinted with paternal silencing in human brain and similar silencing of the Ube3a locus in Purkinje cells and hippocampal neurons in the mouse. We have sequenced the major coding exons for UBE3A in 56 index patients with a clinical diagnosis of AS and a normal DNA methylation pattern. The analysis identified disease-causing mutations in 17 of 56 patients (30%) including 13 truncating mutations, two missense mutations, one single amino acid deletion and one stop codon mutation predicting an elongated protein. Mutations were identified in six of eight families (75%) with more than one affected case, and in 11 of 47 isolated cases (23%); no mutation was found in one family with two siblings, one with a typical and one with an atypical phenotype. Mutations were de novo in nine of the 11 isolated cases. An amino acid polymorphism of threonine substituted for alanine at codon 178 was identified, and a 3 bp length polymorphism was found in the intron upstream of exon 8. In all informative cases, phenotypic expression was consistent with imprinting with a normal phenotype when a mutation was on the paternal chromosome and an AS phenotype when a mutation was on the maternal chromosome. Laboratory diagnosis and genetic counseling for AS are complex, and mutation analysis is valuable in clinically typical AS patients with a normal methylation analysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9887341     DOI: 10.1093/hmg/8.1.129

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  46 in total

Review 1.  Genetics of Angelman syndrome.

Authors:  Y Jiang; E Lev-Lehman; J Bressler; T F Tsai; A L Beaudet
Journal:  Am J Hum Genet       Date:  1999-07       Impact factor: 11.025

2.  Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase.

Authors:  S Nakagawa; J M Huibregtse
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

3.  Quantitative and qualitative analyses of the SNRPN gene using real-time PCR with melting curve analysis.

Authors:  Chia-Cheng Hung; Shin-Yu Lin; Shuan-Pei Lin; Chih-Ping Chen; Lang-Yao Chen; Chien-Nan Lee; Yi-Ning Su
Journal:  J Mol Diagn       Date:  2011-09-01       Impact factor: 5.568

4.  Generation of ES cells for conditional expression of nuclear receptors and coregulators in vivo.

Authors:  San-Pin Wu; Dong-Kee Lee; Francesco J Demayo; Sophia Y Tsai; Ming-Jer Tsai
Journal:  Mol Endocrinol       Date:  2010-04-09

5.  The Genetic Control of Stoichiometry Underlying Autism.

Authors:  Robert B Darnell
Journal:  Annu Rev Neurosci       Date:  2020-07-08       Impact factor: 12.449

6.  An Unbiased Drug Screen for Seizure Suppressors in Duplication 15q Syndrome Reveals 5-HT1A and Dopamine Pathway Activation as Potential Therapies.

Authors:  Bidisha Roy; Jungsoo Han; Kevin A Hope; Tracy L Peters; Glen Palmer; Lawrence T Reiter
Journal:  Biol Psychiatry       Date:  2020-04-13       Impact factor: 13.382

7.  Distinct phenotypes distinguish the molecular classes of Angelman syndrome.

Authors:  A C Lossie; M M Whitney; D Amidon; H J Dong; P Chen; D Theriaque; A Hutson; R D Nicholls; R T Zori; C A Williams; D J Driscoll
Journal:  J Med Genet       Date:  2001-12       Impact factor: 6.318

8.  Angelman syndrome resulting from UBE3A mutations in 14 patients from eight families: clinical manifestations and genetic counselling.

Authors:  A Moncla; P Malzac; M O Livet; M A Voelckel; J Mancini; J C Delaroziere; N Philip; J F Mattei
Journal:  J Med Genet       Date:  1999-07       Impact factor: 6.318

9.  Role of the ubiquitin ligase E6AP/UBE3A in controlling levels of the synaptic protein Arc.

Authors:  Simone Kühnle; Benedikt Mothes; Konstantin Matentzoglu; Martin Scheffner
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

10.  A Drosophila model for Angelman syndrome.

Authors:  Yaning Wu; Francois V Bolduc; Kimberly Bell; Tim Tully; Yanshan Fang; Amita Sehgal; Janice A Fischer
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.